Fresh-frozen plasma vs. plasma protein derivative as adjunctive therapy for patients with massive burns.
Twenty patients with burn injuries involving 45% or more total body surface area were randomly allocated to receive either fresh-frozen plasma (plasma), 200 ml/m2/d (11 patients), or an approximately equal amount of plasma protein derivative (Plasmanate) (nine patients) during the first 45 days postburn. To study the potential effects of these two adjunctive therapies on host resistance to infection, measurements were made twice weekly of the antibacterial funciton of neutrophils, the opsonic index (ability to opsonize alternative pathway dependent E. coli 075), C3(B), IgG, properdin, factor B, total protein, and albumin. The average size of burn in the plasma group was 61.5% total and 42% 3 degrees compared with 61% total and 46% 3 degrees in the Plasmanate group. Ten and 18 episodes of bacteremia occurred in the plasma and Plasmanate groups, respectively. Analysis of the results indicates only slightly better support of host resistance when plasma is administered, but this is counterbalanced by the increased risk of viral hepatitis.
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control; D001798:Blood Proteins / Q000378:metabolism / Q000627:therapeutic use*; D001803:Blood Transfusion; D002056:Burns / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D003176:Complement C3 / Q000378:metabolism; D011415:Complement Factor B / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D009504:Neutrophils / Q000502:physiology; D009895:Opsonin Proteins / Q000502:physiology; D010949:Plasma; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011414:Properdin / Q000378:metabolism; D012709:Serum Albumin / Q000378:metabolism
D001798:Blood Proteins; D003176:Complement C3; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D010952:Plasma Substitutes; D012709:Serum Albumin; D011414:Properdin; D011415:Complement Factor B